Comments
Loading...

BeOne Medicines Analyst Ratings

ONCNASDAQ
Logo brought to you by Benzinga Data
$241.20
-13.29-5.22%
At close: -
$245.00
3.801.58%
After Hours: Jun 27, 2:03 AM EDT
Consensus Rating1
Outperform
Highest Price Target1
$350.00
Lowest Price Target1
$311.00
Consensus Price Target1
$325.56

BeOne Medicines Analyst Ratings and Price Targets | NASDAQ:ONC | Benzinga

BeOne Medicines Ltd has a consensus price target of $325.56 based on the ratings of 9 analysts. The high is $350 issued by Guggenheim on May 8, 2025. The low is $311 issued by RBC Capital on June 27, 2025. The 3 most-recent analyst ratings were released by Morgan Stanley, JP Morgan, and RBC Capital on June 27, 2025, respectively. With an average price target of $320.67 between Morgan Stanley, JP Morgan, and RBC Capital, there's an implied 30.88% upside for BeOne Medicines Ltd from these most-recent analyst ratings.

Analyst Trends and Forecast
1
Feb
6
Apr
2
May
3
Jun
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
4.5
Strong Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Morgan Stanley
JP Morgan
RBC Capital
RBC Capital
Guggenheim

1calculated from analyst ratings

Analyst Ratings for BeOne Medicines

Buy NowGet Alert
06/27/2025Buy Now34.69%Morgan Stanley
Sean Laaman72%
$313 → $330MaintainsOverweightGet Alert
06/27/2025Buy Now31.02%JP Morgan
Jessica Fye67%
$317 → $321MaintainsOverweightGet Alert
06/27/2025Buy Now26.94%RBC Capital
Leonid Timashev40%
$311 → $311ReiteratesOutperform → OutperformGet Alert
05/08/2025Buy Now26.94%RBC Capital
Gregory Renza51%
$312 → $311MaintainsOutperformGet Alert
05/08/2025Buy Now42.86%Guggenheim
Michael Schmidt66%
$348 → $350MaintainsBuyGet Alert
04/28/2025Buy Now27.35%RBC Capital
Gregory Renza51%
$312 → $312ReiteratesOutperform → OutperformGet Alert
04/24/2025Buy Now36.33%TD Securities
Yaron Werber37%
$334 → $334ReiteratesBuy → BuyGet Alert
04/21/2025Buy Now29.39%JP Morgan
Jessica Fye67%
$311 → $317MaintainsOverweightGet Alert
04/16/2025Buy NowGuggenheim
Michael Schmidt66%
ReiteratesBuy → BuyGet Alert
04/10/2025Buy Now42.04%Guggenheim
Michael Schmidt66%
$348 → $348ReiteratesBuy → BuyGet Alert
04/07/2025Buy Now27.35%RBC Capital
Greg Renza65%
→ $312Initiates → OutperformGet Alert
02/28/2025Buy Now27.76%Macquarie
Tony Ren13%
$259 → $313MaintainsOutperformGet Alert
02/28/2025Buy Now42.04%Citizens Capital Markets
Matthew Carletti84%
$288 → $348MaintainsMarket OutperformGet Alert

FAQ

Q

What is the target price for BeOne Medicines (ONC) stock?

A

The latest price target for BeOne Medicines (NASDAQ:ONC) was reported by Morgan Stanley on June 27, 2025. The analyst firm set a price target for $330.00 expecting ONC to rise to within 12 months (a possible 34.69% upside). 13 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for BeOne Medicines (ONC)?

A

The latest analyst rating for BeOne Medicines (NASDAQ:ONC) was provided by Morgan Stanley, and BeOne Medicines maintained their overweight rating.

Q

When was the last upgrade for BeOne Medicines (ONC)?

A

There is no last upgrade for BeOne Medicines

Q

When was the last downgrade for BeOne Medicines (ONC)?

A

There is no last downgrade for BeOne Medicines.

Q

When is the next analyst rating going to be posted or updated for BeOne Medicines (ONC)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BeOne Medicines, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BeOne Medicines was filed on June 27, 2025 so you should expect the next rating to be made available sometime around June 27, 2026.

Q

Is the Analyst Rating BeOne Medicines (ONC) correct?

A

While ratings are subjective and will change, the latest BeOne Medicines (ONC) rating was a maintained with a price target of $313.00 to $330.00. The current price BeOne Medicines (ONC) is trading at is $245.00, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch